Lantus site tops in consumer satisfaction: study

Share this article:

The product site for Sanofi-Aventis's insulin injection Lantus received the highest mark in terms of consumer satisfaction, according to a Manhattan Research study.

The website (which features optional registration for the “Lantus Connection” community and support program) provides “real stories, real tips and real support” for diabetics, and offers “healthcare professional visit guides” in pdf form for download.

In order to join the Lantus community, consumers must input basic information, such as name, address, type of diabetes, current treatments, results from the most recent A1C test and answer several attitudinal statements. For example, registrants are asked whether their diabetes is “completely under control,” if they “feel frazzled by not being able to control my blood sugar” and if they are “interested in learning about insulin,” and whether “having to go on (having gone on) insulin means that I have failed at controlling my blood sugar.” After providing this information, consumers presumably receive a customized newsletter via email.

Other top brand sites, according to the study, are GlaxoSmithKline's Advair website and Merck's Singulair website, coming in at number two and three, respectively.

The following sites also received high consumer satisfaction levels, according to the study: Bristol-Myers Squibb's Abilify, Pfizer's Caduet, Merck's Januvia, Bayer's Mirena, AstraZeneca's Nexium/purplepill.com, Takeda's Prevacid and Wyeth's Protonix.

“While driving visitors to sites is critical, engaging and retaining them will provide the most strategic value to the brand,” said Mark Bard, president of Manhattan Research, in a statement.

Share this article:

Email Newsletters

More in News

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.

Gilead, Merck HCV marketing battle may be on horizon

Gilead, Merck HCV marketing battle may be on ...

Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.